Eli Lilly selects Pennsylvania for $3.5bn manufacturing site of obesity drugs
Eli Lilly has chosen Pennsylvania to house a new $3.5bn manufacturing facility that will produce a forthcoming wave of new…
02 Feb 2026
Amgen hands back eczema drug to Kyowa Kirin despite positive late-stage data
Amgen is handing back the rights of its successful in-licensed atopic dermatitis (AD) asset, rocatinlimab, to Kyowa Kirin. In a statement to Pharmaceutical Technology, an Amgen spokesperson noted that this…
02 Feb 2026
CHMP grants positive opinion for J&J’s Akeega use
Johnson & Johnson (J&J) has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) and recommended an indication extension for Akeega…
02 Feb 2026
CIRM unveils RAPID funding programme for rare diseases
The California Institute for Regenerative Medicine (CIRM) in the US has approved the Rare Disease Acceleration Platform and Innovation and Delivery (RAPID) funding programme, setting aside $100m over two years.…
30 Jan 2026
FDA’s new scheme to boost US manufacturing commences despite uncertainty
The US Food and Drug Administration (FDA) will start accepting applications for the new PreCheck scheme that will streamline the introduction of new pharmaceutical manufacturing facilities in the US, commissioner…
30 Jan 2026
Sanofi touts strong new launch sales amid looming Dupixent patent expiry
Sanofi is making successful strides to restock its pipeline and shore up revenue streams amid the looming patent expiry of its best-selling asset, Dupixent (dupilumab). In FY2025, the French pharmaceutical…
30 Jan 2026
AstraZeneca signs $18.5bn weight loss drug deal with CSPC
AstraZeneca has outlaid up to $18.5bn in a licensing deal with China-based CSPC Pharmaceuticals to develop longer lasting weight-loss drugs, becoming the latest drugmaker to eye entry into the lucrative…